文献速递癫痫

癫痫患者双相症状或双相障碍的患病率:系统综述与Meta分析

Prevalence of Bipolar Symptoms or Disorder in Epilepsy: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2022-03-15

该系统综述与Meta分析(PROSPERO:CRD42021249336)检索4个数据库,纳入17项报告癫痫患者双相症状或双相障碍终身患病率的研究。癫痫患者双相症状的合并患病率为12.3%(95%CI 10.6%-14.1%),双相障碍的合并患病率为4.5%(95%CI 2.2%-7.4%),异质性较高,证据确定性是主要局限。

要点

  • 癫痫患者双相症状合并患病率为12.3%(95%CI 10.6%-14.1%)。
  • 癫痫患者双相障碍合并患病率为4.5%(95%CI 2.2%-7.4%)。
  • 鉴于双相障碍相关显著疾病负担,临床医生应仔细筛查癫痫患者的双相症状。

核心结论

  • 癫痫患者双相症状合并患病率为12.3%(95%CI 10.6%-14.1%),双相障碍合并患病率为4.5%(95%CI 2.2%-7.4%)。
  • 研究主要局限在于证据确定性,但患病率估计应促进对癫痫患者双相症状或双相障碍的进一步研究。
  • 鉴于双相障碍相关的显著疾病负担,临床医生应仔细筛查癫痫患者的双相症状。

研究设计与样本

  • 系统综述与Meta分析(PROSPERO:CRD42021249336),2021年6月5日检索MEDLINE/PubMed、Ovid EMBASE、Ovid APA PsycInfo和Web of Science,无语言或发表时间限制。
  • 纳入标准:原创研究、含横断面研究设计成分、报告双相症状或双相障碍终身患病率或提供足够信息计算估计值、报告判定双相的方法;排除仅基于儿童人群的研究。
  • 共筛选750条记录,纳入17项研究:7项仅提供双相症状患病率估计,8项仅提供双相障碍,2项同时提供两者。
  • 采用两个随机效应Meta分析模型分别计算双相症状和双相障碍的合并终身患病率;使用标准化评估工具评价偏倚风险,采用GRADE方法评价证据确定性。

主要发现

  • 排除离群值并以筛查方法为调节变量进行亚组分析后,癫痫患者双相症状合并患病率为12.3%(95%CI 10.6%-14.1%)(7,506例癫痫患者)。
  • 癫痫患者双相障碍合并患病率为4.5%(95%CI 2.2%-7.4%)(48,334例癫痫患者)。
  • 存在相当大异质性,双相障碍较双相症状更明显,可通过人群人口学差异和研究方法学差异解释。

临床怎么用

  • 作者认为,鉴于双相障碍相关的显著疾病负担,临床医生应仔细筛查癫痫患者的双相症状。

局限性

  • 本研究的主要局限在于证据确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: This systematic review with meta-analysis (PROSPERO: CRD42021249336) was performed to estimate the pooled lifetime prevalence of bipolar symptoms (BS) and bipolar disorder (BD) in people with epilepsy (PWE). METHODS: A search was performed on June 5, 2021, in 4 databases (MEDLINE/PubMed, Ovid EMBASE, Ovid APA PsycInfo, and Web of Science) for original research reporting on BS/BD in PWE, with no restriction on language or time of publication. Inclusion criteria were as follows: (1) original research, (2) cross-sectional study design component, (3) reported lifetime prevalence of BS/BD or enough information to calculate an estimate, and (4) reported the method by which participants were deemed bipolar. Studies based on an exclusively pediatric population were excluded. To calculate pooled lifetime prevalence of BS/BD, 2 meta-analytic random-effects models were fitted, one for BS and the other for BD. Risk of bias was assessed using a standardized appraisal tool for studies reporting prevalence. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. RESULTS: A total of 750 records were screened and 17 studies were included for analysis: 7 provided prevalence estimates for only BS, 8 for only BD, and 2 for both BS and BD. After outlier exclusion and subgroup analysis using screening method as a moderator, the pooled prevalence of BS in PWE was 12.3% (95% CI 10.6%-14.1%) (7,506 PWE). The pooled prevalence of BD in PWE was 4.5% (95% CI 2.2%-7.4%) (48,334 PWE). Considerable heterogeneity was present, more so for BD than for BS, and could be explained through differences in population demographics and study methodology. DISCUSSION: This study's main limitation was regarding the certainty of evidence. However, our estimates of prevalence should prompt further research on BS/BD in PWE. Given the significant morbidity associated with BD, clinicians should carefully screen PWE for BS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Li J, Ledoux-Hutchinson L, Toffa DH, et al. Prevalence of Bipolar Symptoms or Disorder in Epilepsy: A Systematic Review and Meta-analysis. Neurology. 2022. PMID: 35292556. doi:10.1212/WNL.0000000000200186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。